Human Primary Epithelial Cell Models: Promising Tools in the Era of Cystic Fibrosis Personalized Medicine

Cystic fibrosis (CF) is an inherited disorder where individual disease etiology and response to therapeutic intervention is impacted by CF transmembrane regulator (CFTR) mutations and other genetic modifiers. CFTR regulates multiple mechanisms in a diverse range of epithelial tissues. In this Review...

Full description

Bibliographic Details
Main Authors: Awatade, N., Wong, S., Hewson, C., Fawcett, L., Kicic, Anthony, Jaffe, A., Waters, S.
Format: Journal Article
Language:English
Published: FRONTIERS MEDIA SA 2018
Subjects:
Online Access:http://hdl.handle.net/20.500.11937/76772
_version_ 1848763755060527104
author Awatade, N.
Wong, S.
Hewson, C.
Fawcett, L.
Kicic, Anthony
Jaffe, A.
Waters, S.
author_facet Awatade, N.
Wong, S.
Hewson, C.
Fawcett, L.
Kicic, Anthony
Jaffe, A.
Waters, S.
author_sort Awatade, N.
building Curtin Institutional Repository
collection Online Access
description Cystic fibrosis (CF) is an inherited disorder where individual disease etiology and response to therapeutic intervention is impacted by CF transmembrane regulator (CFTR) mutations and other genetic modifiers. CFTR regulates multiple mechanisms in a diverse range of epithelial tissues. In this Review, we consolidate the latest updates in the development of primary epithelial cellular model systems relevant for CF. We discuss conventional two-dimensional (2-D) airway epithelial cell cultures, the backbone of in vitro cellular models to date, as well as improved expansion protocols to overcome finite supply of the cellular source. We highlight a range of strategies for establishment of three dimensional (3-D) airway and intestinal organoid models and evaluate the limitations and potential improvements in each system, focusing on their application in CF. The in vitro CFTR functional assays in patient-derived organoids allow for preclinical pharmacotherapy screening to identify responsive patients. It is likely that organoids will be an invaluable preclinical tool to unravel disease mechanisms, design novel treatments, and enable clinicians to provide personalized management for patients with CF.
first_indexed 2025-11-14T11:08:30Z
format Journal Article
id curtin-20.500.11937-76772
institution Curtin University Malaysia
institution_category Local University
language English
last_indexed 2025-11-14T11:08:30Z
publishDate 2018
publisher FRONTIERS MEDIA SA
recordtype eprints
repository_type Digital Repository
spelling curtin-20.500.11937-767722019-11-11T03:30:42Z Human Primary Epithelial Cell Models: Promising Tools in the Era of Cystic Fibrosis Personalized Medicine Awatade, N. Wong, S. Hewson, C. Fawcett, L. Kicic, Anthony Jaffe, A. Waters, S. Science & Technology Life Sciences & Biomedicine Pharmacology & Pharmacy cystic fibrosis organoid personalized medicine CFTR drug development sweat chloride CFTR modulator INTESTINAL CURRENT MEASUREMENT IN-VITRO CFTR POTENTIATOR TEZACAFTOR-IVACAFTOR ION-TRANSPORT REGENERATION LUMACAFTOR ABSORPTION CORRECTORS SPHEROIDS Cystic fibrosis (CF) is an inherited disorder where individual disease etiology and response to therapeutic intervention is impacted by CF transmembrane regulator (CFTR) mutations and other genetic modifiers. CFTR regulates multiple mechanisms in a diverse range of epithelial tissues. In this Review, we consolidate the latest updates in the development of primary epithelial cellular model systems relevant for CF. We discuss conventional two-dimensional (2-D) airway epithelial cell cultures, the backbone of in vitro cellular models to date, as well as improved expansion protocols to overcome finite supply of the cellular source. We highlight a range of strategies for establishment of three dimensional (3-D) airway and intestinal organoid models and evaluate the limitations and potential improvements in each system, focusing on their application in CF. The in vitro CFTR functional assays in patient-derived organoids allow for preclinical pharmacotherapy screening to identify responsive patients. It is likely that organoids will be an invaluable preclinical tool to unravel disease mechanisms, design novel treatments, and enable clinicians to provide personalized management for patients with CF. 2018 Journal Article http://hdl.handle.net/20.500.11937/76772 10.3389/fphar.2018.01429 English http://creativecommons.org/licenses/by/4.0/ FRONTIERS MEDIA SA fulltext
spellingShingle Science & Technology
Life Sciences & Biomedicine
Pharmacology & Pharmacy
cystic fibrosis
organoid
personalized medicine
CFTR
drug development
sweat chloride
CFTR modulator
INTESTINAL CURRENT MEASUREMENT
IN-VITRO
CFTR POTENTIATOR
TEZACAFTOR-IVACAFTOR
ION-TRANSPORT
REGENERATION
LUMACAFTOR
ABSORPTION
CORRECTORS
SPHEROIDS
Awatade, N.
Wong, S.
Hewson, C.
Fawcett, L.
Kicic, Anthony
Jaffe, A.
Waters, S.
Human Primary Epithelial Cell Models: Promising Tools in the Era of Cystic Fibrosis Personalized Medicine
title Human Primary Epithelial Cell Models: Promising Tools in the Era of Cystic Fibrosis Personalized Medicine
title_full Human Primary Epithelial Cell Models: Promising Tools in the Era of Cystic Fibrosis Personalized Medicine
title_fullStr Human Primary Epithelial Cell Models: Promising Tools in the Era of Cystic Fibrosis Personalized Medicine
title_full_unstemmed Human Primary Epithelial Cell Models: Promising Tools in the Era of Cystic Fibrosis Personalized Medicine
title_short Human Primary Epithelial Cell Models: Promising Tools in the Era of Cystic Fibrosis Personalized Medicine
title_sort human primary epithelial cell models: promising tools in the era of cystic fibrosis personalized medicine
topic Science & Technology
Life Sciences & Biomedicine
Pharmacology & Pharmacy
cystic fibrosis
organoid
personalized medicine
CFTR
drug development
sweat chloride
CFTR modulator
INTESTINAL CURRENT MEASUREMENT
IN-VITRO
CFTR POTENTIATOR
TEZACAFTOR-IVACAFTOR
ION-TRANSPORT
REGENERATION
LUMACAFTOR
ABSORPTION
CORRECTORS
SPHEROIDS
url http://hdl.handle.net/20.500.11937/76772